Evidence map›Paper›PMID 32075921›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Reply to Vargas and Farhat:

Hassan Safi, David R Sherman, Thomas Dick, David Alland

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Heterogeneous Streptomycin Resistance Level AmongFrontiers in microbiology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Hassan SafiCenter for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ 07103.
David R ShermanCenter for Infectious Disease, Seattle Children's Hospital, Seattle, WA 98105.
Thomas DickCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
David AllandCenter for Emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ 07103; david.alland@rutgers.edu.

Funding

Validation and Application of a Model for Human-like TB Latency in RabbitsU19AI111276 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID, HORN, DAVID LOUIS · 2014 to 2020
$23.3M
Bacteria and Host in TB TransmissionR01AI147345 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ALLAND, DAVID, ELLNER, JERROLD J. · 2020 to 2025
$8.7M
Target based discovery of next generation pyrazinamideR01AI106398 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DICK, THOMAS · 2013 to 2022
$7.1M
De facto monotherapy during multidrug TB treatment and emergence of resistanceR01AI111967 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID, DARTOIS, VERONIQUE · 2014 to 2018
$4.2M
NIAID NIH HHS R01 AI106398NIAID NIH HHS R01 AI111967NIAID NIH HHS R01 AI147345NIAID NIH HHS U19 AI111276
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

TuberculosisAntitubercular AgentsDrug ToleranceHumansMycobacterium tuberculosisAntitubercular Agents

Identifiers

PMID32075921
PMCPMC7049110

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.